Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Elevated blood favipiravir levels are inversely associated with ferritin levels and induce the elevation of uric acid levels in COVID-19 treatment: A retrospective single-center study
Authors
Keywords
COVID-19, Favipiravir, Blood level, HPLC, Ferritin, Uric acid
Journal
JOURNAL OF INFECTION AND CHEMOTHERAPY
Volume 28, Issue 1, Pages 73-77
Publisher
Elsevier BV
Online
2021-10-20
DOI
10.1016/j.jiac.2021.10.011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19
- (2021) Yukiko MORIIWA et al. ANALYTICAL SCIENCES
- Population pharmacokinetics of favipiravir in patients with COVID‐19
- (2021) Kei Irie et al. CPT-Pharmacometrics & Systems Pharmacology
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
- (2020) Andrey A Ivashchenko et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents
- (2020) Markus Zeitlinger et al. CLINICAL PHARMACOKINETICS
- A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19
- (2020) Yohei Doi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis
- (2020) Petek Eylul Taneri et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
- (2020) Dhan Bahadur Shrestha et al. Virology Journal
- Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
- (2020) Faryal Khamis et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza
- (2020) Yeming Wang et al. EBioMedicine
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
- (2017) Thi Huyen Tram Nguyen et al. PLoS Neglected Tropical Diseases
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started